tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wilson CH et al. | Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. | 2004 | Ann. Transplant. | pmid:15478912 |
| Foroncewicz B et al. | A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. | 2013 | Ann. Transplant. | pmid:23896824 |
| Arreola-Guerra JM et al. | Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. | 2016 | Ann. Transplant. | pmid:26879833 |
| Mocchegiani F et al. | Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. | 2014 | Ann. Transplant. | pmid:25347718 |
| Hakeam HA et al. | Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. | 2008 | Ann. Transplant. | pmid:18566560 |
| Bäckman L and Persson CA | An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. | 2014 | Ann. Transplant. | pmid:24637379 |
| Girman P et al. | The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. | 2001 | Ann. Transplant. | pmid:11803619 |
| Steinebrunner N et al. | Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. | 2014 | Ann. Transplant. | pmid:24457606 |
| Wu YJ et al. | Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:26782179 |
| Gijsen VM et al. | Tacrolimus-induced nephrotoxicity and genetic variability: a review. | 2012 Apr-Jun | Ann. Transplant. | pmid:22743729 |
| Czubkowski P et al. | Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation. | 2014 | Ann. Transplant. | pmid:25409773 |
| Baron PW et al. | Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. | 2017 | Ann. Transplant. | pmid:28533501 |
| Furmańczyk A et al. | Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation. | 2009 Oct-Dec | Ann. Transplant. | pmid:20009155 |
| Gerlach UA et al. | Aspergillus spondylodiscitis after multivisceral transplantation. | 2009 Oct-Dec | Ann. Transplant. | pmid:20009156 |
| Aguiar D et al. | Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. | 2017 | Ann. Transplant. | pmid:28461684 |
| Malinowski M et al. | Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. | 2010 Jul-Sep | Ann. Transplant. | pmid:20877268 |
| Roan JN et al. | Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. | 2013 | Ann. Transplant. | pmid:23792500 |
| Tanaka T et al. | Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. | 2013 | Ann. Transplant. | pmid:23792533 |
| Ueda K et al. | Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. | 2014 | Ann. Transplant. | pmid:24535029 |
| El-Agroudy AE et al. | Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. | 2008 | Ann. Transplant. | pmid:19034223 |
| Augusto JF et al. | Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. | 2013 | Ann. Transplant. | pmid:23872516 |
| Miyata Y et al. | Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. | 2016 | Ann. Transplant. | pmid:27503662 |
| Mizuno S et al. | Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. | 2013 | Ann. Transplant. | pmid:23845965 |
| Kuypers DR | Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. | 2008 | Ann. Transplant. | pmid:18806728 |
| Grenda R et al. | Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients--a retrospective study. | 2009 Jul-Sep | Ann. Transplant. | pmid:19644155 |
| Basu A et al. | Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. | 2011 Jul-Sep | Ann. Transplant. | pmid:21959503 |
| Fukazawa K et al. | Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. | 2011 Jul-Sep | Ann. Transplant. | pmid:21959523 |
| Zegarska J et al. | Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. | 2015 | Ann. Transplant. | pmid:26313036 |
| Acott P and Babel N | BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? | 2012 Jan-Mar | Ann. Transplant. | pmid:22466913 |
| Bułanowski M et al. | Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. | 2012 Jul-Sep | Ann. Transplant. | pmid:23018257 |
| Schmid S et al. | Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection. | 2014 | Ann. Transplant. | pmid:25123847 |
| Baran DA and Galin ID | "One size fits all": immunosuppression in cardiac transplantation. | 2003 | Ann. Transplant. | pmid:12848376 |
| Remiszewski P et al. | Orthotopic liver transplantation for acute liver failure resulting from "acute fatty liver of pregnancy". | 2003 | Ann. Transplant. | pmid:15114933 |
| Dedinská I et al. | Waist circumference as an independent risk factor for NODAT. | 2015 | Ann. Transplant. | pmid:25791039 |
| Eguchi S et al. | Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. | 2007 | Ann. Transplant. | pmid:18344932 |
| Garaix F et al. | Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. | 2018 | Ann. Transplant. | pmid:30093607 |
| Matia I et al. | Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. | 2014 | Ann. Transplant. | pmid:24815872 |
| Gardiner KM et al. | Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. | 2016 | Ann. Transplant. | pmid:26729299 |
| Provenzani A et al. | The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. | 2009 Jan-Mar | Ann. Transplant. | pmid:19289993 |
| Urbanowicz T et al. | Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. | 2014 | Ann. Transplant. | pmid:24949728 |
| Tang JT et al. | A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. | 2018 | Ann. Transplant. | pmid:29735966 |
| Fuchs U et al. | Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. | 2014 | Ann. Transplant. | pmid:24953848 |
| Wu P et al. | Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. | 2011 Jan-Mar | Ann. Transplant. | pmid:21436775 |
| Foroncewicz B et al. | Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. | 2014 | Ann. Transplant. | pmid:25163829 |
| Bösmüller C et al. | Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. | 2012 | Ann. Transplant. | pmid:23274323 |
| Olczak-Kowalczyk D et al. | The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. | 2012 | Ann. Transplant. | pmid:23274327 |
| Zakliczyński M et al. | Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. | 2005 | Ann. Transplant. | pmid:16218032 |
| Garlicki M et al. | Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. | 2006 | Ann. Transplant. | pmid:17025026 |
| Ruangkanchanasetr P et al. | Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. | 2016 | Ann. Transplant. | pmid:27980321 |
| Kishida N et al. | Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27956735 |
| Illsinger S et al. | Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. | 2011 Apr-Jun | Ann. Transplant. | pmid:21716189 |
| Duvoux C et al. | Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. | 2015 | Ann. Transplant. | pmid:25588713 |
| Albano L et al. | Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. | 2016 | Ann. Transplant. | pmid:27122116 |
| Thölking G et al. | Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27003330 |
| Snell GI et al. | Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. | 2013 | Ann. Transplant. | pmid:23921892 |
| Wyzgał J et al. | Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. | 2007 | Ann. Transplant. | pmid:18173063 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Schmid FX | Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. | 1993 | Annu Rev Biophys Biomol Struct | pmid:7688608 |
| Sigal NH and Dumont FJ | Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. | 1992 | Annu. Rev. Immunol. | pmid:1375473 |
| Tzakis AG et al. | Intestinal transplantation. | 1994 | Annu. Rev. Med. | pmid:7515221 |
| Hanauer SB and Dassopoulos T | Evolving treatment strategies for inflammatory bowel disease. | 2001 | Annu. Rev. Med. | pmid:11160781 |
| Pratt WB | The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. | 1997 | Annu. Rev. Pharmacol. Toxicol. | pmid:9131255 |
| Nikitin AV | [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors]. | 2014 | Antibiot. Khimioter. | pmid:25051716 |
| Romano S et al. | FK506 binding proteins as targets in anticancer therapy. | 2010 | Anticancer Agents Med Chem | pmid:21182472 |
| Epand RF and Epand RM | The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. | 1991 | Anticancer Drug Des. | pmid:1714737 |
| Jachez B et al. | Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. | 1993 | Anticancer Drugs | pmid:7683935 |
| Yamamoto M et al. | Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. | 1995 | Anticancer Drugs | pmid:7579561 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
| Mizuno K et al. | Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. | 1992 Jan-Feb | Anticancer Res. | pmid:1373592 |
| Pinsk V et al. | Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. | 2017 | Anticancer Res. | pmid:28551651 |
| Kalas W et al. | FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. | 2003 Mar-Apr | Anticancer Res. | pmid:12820430 |
| Harada N et al. | Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. | 2018 | Anticancer Res. | pmid:30194210 |
| Ling G et al. | Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. | 2018 | Anticancer Res. | pmid:29848681 |
| Morisaki T et al. | A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. | 2000 Sep- Oct | Anticancer Res. | pmid:11131636 |
| Gornet JM et al. | Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. | 2001 Nov-Dec | Anticancer Res. | pmid:11911319 |
| Gauthier C et al. | Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. | 2003 | Antimicrob. Agents Chemother. | pmid:12709320 |
| Del Poeta M et al. | Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. | 2000 | Antimicrob. Agents Chemother. | pmid:10681348 |
| Steinbach WJ et al. | Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. | 2007 | Antimicrob. Agents Chemother. | pmid:17502415 |
| Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
| Steinbach WJ et al. | In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. | 2004 | Antimicrob. Agents Chemother. | pmid:15105118 |
| Onyewu C et al. | Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. | 2007 | Antimicrob. Agents Chemother. | pmid:17664323 |
| Lamoth F et al. | In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. | 2013 | Antimicrob. Agents Chemother. | pmid:23165466 |
| Fortwendel JR et al. | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. | 2009 | Antimicrob. Agents Chemother. | pmid:19015336 |
| Lamping E et al. | Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. | 2009 | Antimicrob. Agents Chemother. | pmid:19015352 |
| Reedy JL et al. | Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. | 2006 | Antimicrob. Agents Chemother. | pmid:16569889 |
| Morikawa K et al. | Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:7509146 |
| Sun S et al. | In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. | 2008 | Antimicrob. Agents Chemother. | pmid:18056277 |
| Kontoyiannis DP et al. | Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. | 2008 | Antimicrob. Agents Chemother. | pmid:18070977 |
| Ricardo E et al. | In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. | 2014 | Antimicrob. Agents Chemother. | pmid:24867987 |
| Gao L and Sun Y | In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. | 2015 | Antimicrob. Agents Chemother. | pmid:26303797 |
| Odom A et al. | The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. | 1997 | Antimicrob. Agents Chemother. | pmid:8980772 |
| Roy J et al. | The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. | 2002 | Antimicrob. Agents Chemother. | pmid:12384349 |
| Steinbach WJ et al. | In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. | 2004 | Antimicrob. Agents Chemother. | pmid:15561883 |
| Sugita T et al. | A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. | 2006 | Antimicrob. Agents Chemother. | pmid:16870799 |
| Dang W et al. | Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. | 2017 | Antimicrob. Agents Chemother. | pmid:28807916 |
| Aoki Y and Kao PN | Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10543746 |
| Dannaoui E et al. | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. | 2009 | Antimicrob. Agents Chemother. | pmid:19451295 |
| Rivosecchi RM et al. | Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. | 2017 | Antimicrob. Agents Chemother. | pmid:28674051 |
| Rosenwirth B et al. | Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. | 1994 | Antimicrob. Agents Chemother. | pmid:7527198 |
| Venkataramanan R et al. | Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. | 2002 | Antimicrob. Agents Chemother. | pmid:12183280 |